Br J Cancer:FOLFOXIRI和贝伐单抗治疗转移性结直肠癌的临床研究汇总分析

2020-10-17 xiaozeng MedSci原创

FOLFOXIRI(5-氟尿嘧啶、L-亚叶酸、奥沙利铂 oxaliplatin和伊立替康 irinotecan))/贝伐单抗(bevizumab,bev)目前已被证明是转移性结直肠癌(mCRC)患者的

FOLFOXIRI(5-氟尿嘧啶、L-亚叶酸、奥沙利铂 oxaliplatin和伊立替康 irinotecan))/贝伐单抗(bevizumab,bev)目前已被证明是转移性结直肠癌(mCRC)患者的一个有效的一线治疗选择。然而,预先暴露于三种细胞毒性中会引起人们对疾病发展后的治疗效果的担忧。

该研究针对参与两项随机3期临床试验(TRIBE和TRIBE2)的患者进行FOLFOXIRI/bev治疗效果的汇总分析,在该研究中主要比较了FOLFOXIRI/bev和doublets(FOLFOX(5-氟尿嘧啶、L-亚叶酸和奥沙利铂)或FOLFIRI(5-氟尿嘧啶、L-亚叶酸和伊立替康))/bev之间的效果。并评估了治疗期间的缓解率、无进展生存期(第二PFS)和总生存期(第二OS)。而一线的RECIST(实体瘤疗效评价标准)反应以及OIFI(无奥沙利铂和伊立替康间隔)则作为重新引入FOLFOXIRI±bev的潜在预测指标。

TRIBE和TRIBE2汇总分析流程图

结果显示,相比于doublets±bev或其他治疗策略,接受FOLFOXIRI±bev的再次入院的患者的第二次PFS较长(分别为4.4个月、3.9个月和6.1个月),且似乎仅限于在一线治疗中获得缓解的患者(4.2个月和4.7个月对应6.9个月),患者的OIFI≥4个月(分别为6.5个月、4.6个月和7.2个月)。

一线FOLFOXIRI/bev治疗后的第二PFS 和第二OS期结果

总而言之,一线FOLFOXIRI/bev并不影响二线治疗的疗效。一线反应和更长的OIFI则与反应的改善、第二PFS期和FOLFOXIRI±bev治疗策略的重新引入相关,但并不影响第二OS期。


原始出处:

Rossini, D., Lonardi, S., Antoniotti, C. et al. Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONO. Br J Cancer (07 October 2020).

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2053578, encodeId=f3c220535e825, content=<a href='/topic/show?id=5e5b6429291' target=_blank style='color:#2F92EE;'>#汇总分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64292, encryptionId=5e5b6429291, topicName=汇总分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Tue Jul 06 01:54:45 CST 2021, time=2021-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=897968, encodeId=54d389e968b4, content=<a href='/topic/show?id=7b8ae57644' target=_blank style='color:#2F92EE;'>#FOLFOXIRI#</a>和<a href='/topic/show?id=aeef922031b' target=_blank style='color:#2F92EE;'>#贝伐单抗#</a>治疗转移性<a href='/topic/show?id=493ae869206' target=_blank style='color:#2F92EE;'>#结直肠癌#</a>,贝伐越来越变成万金油!, beContent=null, objectType=article, channel=null, level=null, likeNumber=186, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7576, encryptionId=7b8ae57644, topicName=FOLFOXIRI), TopicDto(id=92203, encryptionId=aeef922031b, topicName=贝伐单抗), TopicDto(id=78692, encryptionId=493ae869206, topicName=结直肠癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Mon Nov 09 15:03:53 CST 2020, time=2020-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=893124, encodeId=5ea6893124fb, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8212476654, createdName=1244c0ebm28暂无昵称, createdTime=Mon Oct 19 18:26:03 CST 2020, time=2020-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386674, encodeId=546313866e475, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Mon Oct 19 14:54:45 CST 2020, time=2020-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1453431, encodeId=392d145343180, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Mon Oct 19 14:54:45 CST 2020, time=2020-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455464, encodeId=6f6a145546418, content=<a href='/topic/show?id=d0cee572e9' target=_blank style='color:#2F92EE;'>#FOLFOX#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7572, encryptionId=d0cee572e9, topicName=FOLFOX)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12f25658567, createdName=linlin2314, createdTime=Mon Oct 19 14:54:45 CST 2020, time=2020-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477062, encodeId=305414e7062c8, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92202, encryptionId=c32e9220221, topicName=贝伐)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef557344179, createdName=sunrural_42825359, createdTime=Mon Oct 19 14:54:45 CST 2020, time=2020-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=892783, encodeId=5a81892e836b, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/9iaAb4Jw2bbQql9icNGa5FjbmPicfSE7biaQIwz1AApCvib4HUmz3W6DibibX6BAgp4atWt9Qkox88aPJQY6GkvckxdfQ/132, createdBy=448e5312462, createdName=陈小凤, createdTime=Sun Oct 18 09:31:18 CST 2020, time=2020-10-18, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2053578, encodeId=f3c220535e825, content=<a href='/topic/show?id=5e5b6429291' target=_blank style='color:#2F92EE;'>#汇总分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64292, encryptionId=5e5b6429291, topicName=汇总分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Tue Jul 06 01:54:45 CST 2021, time=2021-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=897968, encodeId=54d389e968b4, content=<a href='/topic/show?id=7b8ae57644' target=_blank style='color:#2F92EE;'>#FOLFOXIRI#</a>和<a href='/topic/show?id=aeef922031b' target=_blank style='color:#2F92EE;'>#贝伐单抗#</a>治疗转移性<a href='/topic/show?id=493ae869206' target=_blank style='color:#2F92EE;'>#结直肠癌#</a>,贝伐越来越变成万金油!, beContent=null, objectType=article, channel=null, level=null, likeNumber=186, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7576, encryptionId=7b8ae57644, topicName=FOLFOXIRI), TopicDto(id=92203, encryptionId=aeef922031b, topicName=贝伐单抗), TopicDto(id=78692, encryptionId=493ae869206, topicName=结直肠癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Mon Nov 09 15:03:53 CST 2020, time=2020-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=893124, encodeId=5ea6893124fb, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8212476654, createdName=1244c0ebm28暂无昵称, createdTime=Mon Oct 19 18:26:03 CST 2020, time=2020-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386674, encodeId=546313866e475, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Mon Oct 19 14:54:45 CST 2020, time=2020-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1453431, encodeId=392d145343180, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Mon Oct 19 14:54:45 CST 2020, time=2020-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455464, encodeId=6f6a145546418, content=<a href='/topic/show?id=d0cee572e9' target=_blank style='color:#2F92EE;'>#FOLFOX#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7572, encryptionId=d0cee572e9, topicName=FOLFOX)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12f25658567, createdName=linlin2314, createdTime=Mon Oct 19 14:54:45 CST 2020, time=2020-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477062, encodeId=305414e7062c8, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92202, encryptionId=c32e9220221, topicName=贝伐)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef557344179, createdName=sunrural_42825359, createdTime=Mon Oct 19 14:54:45 CST 2020, time=2020-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=892783, encodeId=5a81892e836b, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/9iaAb4Jw2bbQql9icNGa5FjbmPicfSE7biaQIwz1AApCvib4HUmz3W6DibibX6BAgp4atWt9Qkox88aPJQY6GkvckxdfQ/132, createdBy=448e5312462, createdName=陈小凤, createdTime=Sun Oct 18 09:31:18 CST 2020, time=2020-10-18, status=1, ipAttribution=)]
    2020-11-09 lovetcm

    #FOLFOXIRI##贝伐单抗#治疗转移性#结直肠癌#,贝伐越来越变成万金油!

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2053578, encodeId=f3c220535e825, content=<a href='/topic/show?id=5e5b6429291' target=_blank style='color:#2F92EE;'>#汇总分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64292, encryptionId=5e5b6429291, topicName=汇总分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Tue Jul 06 01:54:45 CST 2021, time=2021-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=897968, encodeId=54d389e968b4, content=<a href='/topic/show?id=7b8ae57644' target=_blank style='color:#2F92EE;'>#FOLFOXIRI#</a>和<a href='/topic/show?id=aeef922031b' target=_blank style='color:#2F92EE;'>#贝伐单抗#</a>治疗转移性<a href='/topic/show?id=493ae869206' target=_blank style='color:#2F92EE;'>#结直肠癌#</a>,贝伐越来越变成万金油!, beContent=null, objectType=article, channel=null, level=null, likeNumber=186, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7576, encryptionId=7b8ae57644, topicName=FOLFOXIRI), TopicDto(id=92203, encryptionId=aeef922031b, topicName=贝伐单抗), TopicDto(id=78692, encryptionId=493ae869206, topicName=结直肠癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Mon Nov 09 15:03:53 CST 2020, time=2020-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=893124, encodeId=5ea6893124fb, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8212476654, createdName=1244c0ebm28暂无昵称, createdTime=Mon Oct 19 18:26:03 CST 2020, time=2020-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386674, encodeId=546313866e475, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Mon Oct 19 14:54:45 CST 2020, time=2020-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1453431, encodeId=392d145343180, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Mon Oct 19 14:54:45 CST 2020, time=2020-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455464, encodeId=6f6a145546418, content=<a href='/topic/show?id=d0cee572e9' target=_blank style='color:#2F92EE;'>#FOLFOX#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7572, encryptionId=d0cee572e9, topicName=FOLFOX)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12f25658567, createdName=linlin2314, createdTime=Mon Oct 19 14:54:45 CST 2020, time=2020-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477062, encodeId=305414e7062c8, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92202, encryptionId=c32e9220221, topicName=贝伐)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef557344179, createdName=sunrural_42825359, createdTime=Mon Oct 19 14:54:45 CST 2020, time=2020-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=892783, encodeId=5a81892e836b, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/9iaAb4Jw2bbQql9icNGa5FjbmPicfSE7biaQIwz1AApCvib4HUmz3W6DibibX6BAgp4atWt9Qkox88aPJQY6GkvckxdfQ/132, createdBy=448e5312462, createdName=陈小凤, createdTime=Sun Oct 18 09:31:18 CST 2020, time=2020-10-18, status=1, ipAttribution=)]
    2020-10-19 1244c0ebm28暂无昵称

    学习学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2053578, encodeId=f3c220535e825, content=<a href='/topic/show?id=5e5b6429291' target=_blank style='color:#2F92EE;'>#汇总分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64292, encryptionId=5e5b6429291, topicName=汇总分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Tue Jul 06 01:54:45 CST 2021, time=2021-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=897968, encodeId=54d389e968b4, content=<a href='/topic/show?id=7b8ae57644' target=_blank style='color:#2F92EE;'>#FOLFOXIRI#</a>和<a href='/topic/show?id=aeef922031b' target=_blank style='color:#2F92EE;'>#贝伐单抗#</a>治疗转移性<a href='/topic/show?id=493ae869206' target=_blank style='color:#2F92EE;'>#结直肠癌#</a>,贝伐越来越变成万金油!, beContent=null, objectType=article, channel=null, level=null, likeNumber=186, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7576, encryptionId=7b8ae57644, topicName=FOLFOXIRI), TopicDto(id=92203, encryptionId=aeef922031b, topicName=贝伐单抗), TopicDto(id=78692, encryptionId=493ae869206, topicName=结直肠癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Mon Nov 09 15:03:53 CST 2020, time=2020-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=893124, encodeId=5ea6893124fb, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8212476654, createdName=1244c0ebm28暂无昵称, createdTime=Mon Oct 19 18:26:03 CST 2020, time=2020-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386674, encodeId=546313866e475, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Mon Oct 19 14:54:45 CST 2020, time=2020-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1453431, encodeId=392d145343180, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Mon Oct 19 14:54:45 CST 2020, time=2020-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455464, encodeId=6f6a145546418, content=<a href='/topic/show?id=d0cee572e9' target=_blank style='color:#2F92EE;'>#FOLFOX#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7572, encryptionId=d0cee572e9, topicName=FOLFOX)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12f25658567, createdName=linlin2314, createdTime=Mon Oct 19 14:54:45 CST 2020, time=2020-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477062, encodeId=305414e7062c8, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92202, encryptionId=c32e9220221, topicName=贝伐)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef557344179, createdName=sunrural_42825359, createdTime=Mon Oct 19 14:54:45 CST 2020, time=2020-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=892783, encodeId=5a81892e836b, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/9iaAb4Jw2bbQql9icNGa5FjbmPicfSE7biaQIwz1AApCvib4HUmz3W6DibibX6BAgp4atWt9Qkox88aPJQY6GkvckxdfQ/132, createdBy=448e5312462, createdName=陈小凤, createdTime=Sun Oct 18 09:31:18 CST 2020, time=2020-10-18, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2053578, encodeId=f3c220535e825, content=<a href='/topic/show?id=5e5b6429291' target=_blank style='color:#2F92EE;'>#汇总分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64292, encryptionId=5e5b6429291, topicName=汇总分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Tue Jul 06 01:54:45 CST 2021, time=2021-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=897968, encodeId=54d389e968b4, content=<a href='/topic/show?id=7b8ae57644' target=_blank style='color:#2F92EE;'>#FOLFOXIRI#</a>和<a href='/topic/show?id=aeef922031b' target=_blank style='color:#2F92EE;'>#贝伐单抗#</a>治疗转移性<a href='/topic/show?id=493ae869206' target=_blank style='color:#2F92EE;'>#结直肠癌#</a>,贝伐越来越变成万金油!, beContent=null, objectType=article, channel=null, level=null, likeNumber=186, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7576, encryptionId=7b8ae57644, topicName=FOLFOXIRI), TopicDto(id=92203, encryptionId=aeef922031b, topicName=贝伐单抗), TopicDto(id=78692, encryptionId=493ae869206, topicName=结直肠癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Mon Nov 09 15:03:53 CST 2020, time=2020-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=893124, encodeId=5ea6893124fb, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8212476654, createdName=1244c0ebm28暂无昵称, createdTime=Mon Oct 19 18:26:03 CST 2020, time=2020-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386674, encodeId=546313866e475, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Mon Oct 19 14:54:45 CST 2020, time=2020-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1453431, encodeId=392d145343180, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Mon Oct 19 14:54:45 CST 2020, time=2020-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455464, encodeId=6f6a145546418, content=<a href='/topic/show?id=d0cee572e9' target=_blank style='color:#2F92EE;'>#FOLFOX#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7572, encryptionId=d0cee572e9, topicName=FOLFOX)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12f25658567, createdName=linlin2314, createdTime=Mon Oct 19 14:54:45 CST 2020, time=2020-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477062, encodeId=305414e7062c8, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92202, encryptionId=c32e9220221, topicName=贝伐)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef557344179, createdName=sunrural_42825359, createdTime=Mon Oct 19 14:54:45 CST 2020, time=2020-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=892783, encodeId=5a81892e836b, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/9iaAb4Jw2bbQql9icNGa5FjbmPicfSE7biaQIwz1AApCvib4HUmz3W6DibibX6BAgp4atWt9Qkox88aPJQY6GkvckxdfQ/132, createdBy=448e5312462, createdName=陈小凤, createdTime=Sun Oct 18 09:31:18 CST 2020, time=2020-10-18, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2053578, encodeId=f3c220535e825, content=<a href='/topic/show?id=5e5b6429291' target=_blank style='color:#2F92EE;'>#汇总分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64292, encryptionId=5e5b6429291, topicName=汇总分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Tue Jul 06 01:54:45 CST 2021, time=2021-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=897968, encodeId=54d389e968b4, content=<a href='/topic/show?id=7b8ae57644' target=_blank style='color:#2F92EE;'>#FOLFOXIRI#</a>和<a href='/topic/show?id=aeef922031b' target=_blank style='color:#2F92EE;'>#贝伐单抗#</a>治疗转移性<a href='/topic/show?id=493ae869206' target=_blank style='color:#2F92EE;'>#结直肠癌#</a>,贝伐越来越变成万金油!, beContent=null, objectType=article, channel=null, level=null, likeNumber=186, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7576, encryptionId=7b8ae57644, topicName=FOLFOXIRI), TopicDto(id=92203, encryptionId=aeef922031b, topicName=贝伐单抗), TopicDto(id=78692, encryptionId=493ae869206, topicName=结直肠癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Mon Nov 09 15:03:53 CST 2020, time=2020-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=893124, encodeId=5ea6893124fb, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8212476654, createdName=1244c0ebm28暂无昵称, createdTime=Mon Oct 19 18:26:03 CST 2020, time=2020-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386674, encodeId=546313866e475, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Mon Oct 19 14:54:45 CST 2020, time=2020-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1453431, encodeId=392d145343180, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Mon Oct 19 14:54:45 CST 2020, time=2020-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455464, encodeId=6f6a145546418, content=<a href='/topic/show?id=d0cee572e9' target=_blank style='color:#2F92EE;'>#FOLFOX#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7572, encryptionId=d0cee572e9, topicName=FOLFOX)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12f25658567, createdName=linlin2314, createdTime=Mon Oct 19 14:54:45 CST 2020, time=2020-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477062, encodeId=305414e7062c8, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92202, encryptionId=c32e9220221, topicName=贝伐)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef557344179, createdName=sunrural_42825359, createdTime=Mon Oct 19 14:54:45 CST 2020, time=2020-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=892783, encodeId=5a81892e836b, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/9iaAb4Jw2bbQql9icNGa5FjbmPicfSE7biaQIwz1AApCvib4HUmz3W6DibibX6BAgp4atWt9Qkox88aPJQY6GkvckxdfQ/132, createdBy=448e5312462, createdName=陈小凤, createdTime=Sun Oct 18 09:31:18 CST 2020, time=2020-10-18, status=1, ipAttribution=)]
    2020-10-19 linlin2314
  7. [GetPortalCommentsPageByObjectIdResponse(id=2053578, encodeId=f3c220535e825, content=<a href='/topic/show?id=5e5b6429291' target=_blank style='color:#2F92EE;'>#汇总分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64292, encryptionId=5e5b6429291, topicName=汇总分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Tue Jul 06 01:54:45 CST 2021, time=2021-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=897968, encodeId=54d389e968b4, content=<a href='/topic/show?id=7b8ae57644' target=_blank style='color:#2F92EE;'>#FOLFOXIRI#</a>和<a href='/topic/show?id=aeef922031b' target=_blank style='color:#2F92EE;'>#贝伐单抗#</a>治疗转移性<a href='/topic/show?id=493ae869206' target=_blank style='color:#2F92EE;'>#结直肠癌#</a>,贝伐越来越变成万金油!, beContent=null, objectType=article, channel=null, level=null, likeNumber=186, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7576, encryptionId=7b8ae57644, topicName=FOLFOXIRI), TopicDto(id=92203, encryptionId=aeef922031b, topicName=贝伐单抗), TopicDto(id=78692, encryptionId=493ae869206, topicName=结直肠癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Mon Nov 09 15:03:53 CST 2020, time=2020-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=893124, encodeId=5ea6893124fb, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8212476654, createdName=1244c0ebm28暂无昵称, createdTime=Mon Oct 19 18:26:03 CST 2020, time=2020-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386674, encodeId=546313866e475, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Mon Oct 19 14:54:45 CST 2020, time=2020-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1453431, encodeId=392d145343180, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Mon Oct 19 14:54:45 CST 2020, time=2020-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455464, encodeId=6f6a145546418, content=<a href='/topic/show?id=d0cee572e9' target=_blank style='color:#2F92EE;'>#FOLFOX#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7572, encryptionId=d0cee572e9, topicName=FOLFOX)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12f25658567, createdName=linlin2314, createdTime=Mon Oct 19 14:54:45 CST 2020, time=2020-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477062, encodeId=305414e7062c8, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92202, encryptionId=c32e9220221, topicName=贝伐)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef557344179, createdName=sunrural_42825359, createdTime=Mon Oct 19 14:54:45 CST 2020, time=2020-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=892783, encodeId=5a81892e836b, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/9iaAb4Jw2bbQql9icNGa5FjbmPicfSE7biaQIwz1AApCvib4HUmz3W6DibibX6BAgp4atWt9Qkox88aPJQY6GkvckxdfQ/132, createdBy=448e5312462, createdName=陈小凤, createdTime=Sun Oct 18 09:31:18 CST 2020, time=2020-10-18, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=2053578, encodeId=f3c220535e825, content=<a href='/topic/show?id=5e5b6429291' target=_blank style='color:#2F92EE;'>#汇总分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64292, encryptionId=5e5b6429291, topicName=汇总分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Tue Jul 06 01:54:45 CST 2021, time=2021-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=897968, encodeId=54d389e968b4, content=<a href='/topic/show?id=7b8ae57644' target=_blank style='color:#2F92EE;'>#FOLFOXIRI#</a>和<a href='/topic/show?id=aeef922031b' target=_blank style='color:#2F92EE;'>#贝伐单抗#</a>治疗转移性<a href='/topic/show?id=493ae869206' target=_blank style='color:#2F92EE;'>#结直肠癌#</a>,贝伐越来越变成万金油!, beContent=null, objectType=article, channel=null, level=null, likeNumber=186, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7576, encryptionId=7b8ae57644, topicName=FOLFOXIRI), TopicDto(id=92203, encryptionId=aeef922031b, topicName=贝伐单抗), TopicDto(id=78692, encryptionId=493ae869206, topicName=结直肠癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Mon Nov 09 15:03:53 CST 2020, time=2020-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=893124, encodeId=5ea6893124fb, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8212476654, createdName=1244c0ebm28暂无昵称, createdTime=Mon Oct 19 18:26:03 CST 2020, time=2020-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386674, encodeId=546313866e475, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Mon Oct 19 14:54:45 CST 2020, time=2020-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1453431, encodeId=392d145343180, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Mon Oct 19 14:54:45 CST 2020, time=2020-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455464, encodeId=6f6a145546418, content=<a href='/topic/show?id=d0cee572e9' target=_blank style='color:#2F92EE;'>#FOLFOX#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7572, encryptionId=d0cee572e9, topicName=FOLFOX)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12f25658567, createdName=linlin2314, createdTime=Mon Oct 19 14:54:45 CST 2020, time=2020-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477062, encodeId=305414e7062c8, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92202, encryptionId=c32e9220221, topicName=贝伐)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef557344179, createdName=sunrural_42825359, createdTime=Mon Oct 19 14:54:45 CST 2020, time=2020-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=892783, encodeId=5a81892e836b, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/9iaAb4Jw2bbQql9icNGa5FjbmPicfSE7biaQIwz1AApCvib4HUmz3W6DibibX6BAgp4atWt9Qkox88aPJQY6GkvckxdfQ/132, createdBy=448e5312462, createdName=陈小凤, createdTime=Sun Oct 18 09:31:18 CST 2020, time=2020-10-18, status=1, ipAttribution=)]
    2020-10-18 陈小凤

    学习

    0

相关资讯

PD-1单抗Opdivo联合贝伐单抗和化疗:显着改善非小细胞肺癌患者的无进展生存期

与安慰剂组相比,Opdivo组合组在无进展生存期(PFS)的主要终点方面显示出统计学上的显着改善,并且未发现新的安全问题。

三星Bioepis旗下贝伐单抗生物类似物AYBINTIO获CHMP正面评价

韩国三星Bioepis公司近日宣布,欧洲药品管理局(EMA)的人用药品委员会(CHMP)对AYBINTIO持肯定态度,该药品是贝伐单抗的生物类似物。

Clin cancer res:FTD/TPI+伊立替康+贝伐单抗联合治疗晚期消化道肿瘤的疗效和安全性

FTD/TPI+伊立替康+贝伐单抗联合治疗转移性结直肠癌(mCRC)的安全性、药物动力学和FTD抗肿瘤活性目前尚不明确。

LYNPARZA(olaparib)联合贝伐单抗一线治疗HRD阳性晚期卵巢癌:已获FDA首肯

阿斯利康(AstraZeneca)和默克(Merck)今日宣布,美国食品药品监督管理局(FDA)已批准LYNPARZA(olaparib)联合贝伐单抗一线维持治疗晚期上皮性卵巢癌。

Gynecol Oncol:依维莫司和贝伐单抗在复发性卵巢癌,腹膜癌和输卵管癌中的II期研究

复发性卵巢癌、输卵管癌和腹膜癌用传统疗法治愈的可能性有限。依维莫司和贝伐珠单抗在晚期实体瘤中的I期研究的初步结果显示,这是一个很有前景的组合。本研究旨在评估everolimus和贝伐单抗在复发性卵巢癌

J Clin Oncol:III期试验:培美曲塞联合贝伐单抗作为NSCLC患者的维持疗法的有效性和安全性

既往研究表明非小细胞肺癌(NSCLC)患者可从维持治疗中获益。COMPASS试验评估了贝伐单抗联合或不联合培美曲塞作为卡铂+培美曲塞和贝伐单抗诱导化疗后的维持治疗的有效性和安全性。COMPASS试验招募明确无EGFR 19缺失或L858R突变的未治疗过的晚期非鳞状NSCLC患者,予以卡铂、培美曲塞(500mg/m2)和贝伐单抗(15mg/kg)作为一线治疗,每3周用药一次,共4个疗程。在诱导治疗过